During the study, participants will have a baseline assessment of how well their salivary glands work, using a special imaging test called scintigraphy and a simple saliva‑collection test. After the radiation course, the same tests are repeated to compare any changes. An additional scan using ultrasound will look at the size and texture of the glands, and questionnaires will evaluate any feelings of dry mouth and overall quality of life. Safety will be monitored by recording any side effects or problems at the injection site.

The study has more than one part. In the first part, small groups of people receive the drug combinations so that researchers can watch for side effects and choose a dose that can be used more widely. In the later part, more people receive the combinations to learn more about how the treatment works in the different cancer groups and to compare dose options in some groups. Because this is an open-label trial, everyone knows which treatment is being given.

During the trial, the treatment is given over time, and participants are followed closely while they are receiving it and for a period afterward. Doctors check for side effects, how well the cancer seems to respond, and how the body handles the drugs. The study includes people with several cancer types, and the treatment plan may differ depending on the cancer group and the study part.

The purpose of this study is to find out if TUB-030 is safe and well-tolerated by patients, to determine the right dose to use in future studies, and to see if the medicine has any effect on the cancer. The study will also look at how the body processes the medicine by measuring drug levels in the blood at different times. The study has different phases, starting with dose escalation where small groups of patients receive increasing doses to find the maximum safe dose, followed by a dose optimization phase where the most promising dose is tested in larger groups of patients with specific cancer types.

During the study, patients will receive TUB-030 in treatment cycles that last three weeks. The study team will regularly check for side effects, monitor how the cancer responds to treatment using imaging scans, and collect blood samples to measure drug levels and check for immune responses to the medicine. Patients will need to have tissue samples from their tumor available for testing to help understand how the treatment works. The study will continue until the cancer gets worse, side effects become too severe, or the patient and doctor decide to stop treatment.

The purpose of the study is to compare how well the combination of zanzalintinib and pembrolizumab works against using pembrolizumab alone in treating this type of cancer. Participants in the study will be randomly assigned to receive either the combination treatment or pembrolizumab by itself. Some participants may receive a placebo, which looks like the real medication but does not contain the active drug. The study will involve regular check-ups and monitoring to assess the treatment’s effects and any side effects experienced by the participants.

The study will take place over several months, with participants receiving treatment and being monitored for changes in their condition. The goal is to determine if the combination of zanzalintinib and pembrolizumab can improve outcomes for patients with this type of cancer. Participants will be closely observed by medical professionals throughout the study to ensure their safety and to gather important data on the treatment’s effectiveness.

The purpose of the study is to evaluate the safety and effectiveness of ALE.C04 both on its own and in combination with Pembrolizumab. Participants will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will be conducted in phases, starting with small doses to ensure safety and gradually increasing to find the most effective dose. The study will also compare how well ALE.C04 works alone versus when combined with Pembrolizumab.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The study aims to determine the best dosage for future use and to see how well the treatments work in reducing the size of the cancer or stopping its growth. This research is important for developing new treatment options for patients with R/M HNSCC.

The purpose of the study is to determine if adding ficerafusp alfa to pembrolizumab works better than pembrolizumab with placebo for patients who have not received previous treatment for their advanced cancer. The study will test two different doses of ficerafusp alfa (750 mg and 1500 mg) to find the most effective and safest dose when combined with pembrolizumab.

During the treatment, participants will receive regular doses of the study medications for up to 24 months. The study will track how well the treatment works by measuring if the cancer shrinks or disappears (tumor response), how long patients live (overall survival), and how long patients live without their cancer getting worse (progression-free survival). The study will also monitor any side effects that participants may experience during treatment.

The treatment being tested involves the use of ficerafusp alfa (also known as BCA 101) given along with nivolumab. This is being compared to patients receiving only nivolumab. During the study, participants will receive these medications through an intravenous infusion, which is a method where medicine is delivered directly into a vein through a small tube.

Participants will be monitored over time to see how their cancer responds to the treatments. This includes checking if the tumors shrink or disappear and tracking how long the disease stays stable before it potentially starts growing again. The study also tracks how long patients live and any side effects that may occur during the treatment period.

During the study, participants may receive PTT-4256 as an oral tablet. If the combination treatment is used, nivolumab will be administered through an infusion, which is a method of delivering medication directly into a vein. The research involves observing how the body processes these drugs and monitoring for any side effects to determine the best possible dose for patients.

The purpose of this study is to improve how surgeons identify the edges of tumors during surgery and to test whether using fluorescence-guided surgery can help detect tumor margins better in patients with head and neck cancer. The study will compare the surgical results of patients who receive this fluorescence-guided approach with those who receive standard surgical care. The medicine will be given through a vein as an injection or infusion before the surgery takes place.

During the study, patients will undergo their planned surgical removal of the tumor, but the surgical team will use special imaging equipment that can detect the fluorescent signal from the modified cetuximab. This helps the surgeon see whether all the cancer has been removed by looking at the glowing edges during the operation. The study will also look at how well this method works by measuring its accuracy in identifying areas where cancer cells might remain at the surgical margins. Additionally, the study will test a new imaging technique and evaluate how information can be shared between the pathology laboratory and the surgical team during the operation to improve decision-making.

The trial has two parts. The first part is a safety run-in phase where a small group of patients will receive BNT113 combined with pembrolizumab to check if the combination is safe and well-tolerated. The second part is a randomized phase where patients will be assigned by chance to receive either the combination of BNT113 and pembrolizumab or pembrolizumab alone. During the trial, doctors will monitor how the cancer responds to treatment and will check for any side effects. Patients will need to have regular visits, blood tests, and scans to see how well the treatment is working.

The trial will measure several outcomes including how long patients live, how long it takes before the cancer grows or spreads, and whether the cancer shrinks or disappears. Doctors will also carefully track any side effects that occur during treatment. The trial will use imaging scans to measure changes in tumor size and will follow patients for up to several years to gather information about the long-term effects of these treatments.

The purpose of the study is to evaluate how well these new combinations of immune system treatments work compared to dostarlimab alone in people with this type of cancer that shows the PD-L1 marker. The main measure of success will be looking at how many people experience either complete disappearance of their tumors or significant shrinking of their tumors during treatment. Participants will be assigned randomly to receive one of the treatment combinations, and the study will follow them for up to 24 months to track how their cancer responds.

During the study, participants will receive their assigned treatment through infusions into a vein, and doctors will regularly check how the tumors are responding using imaging scans and physical examinations. Tissue samples from the tumor will be needed to confirm that the cancer meets the study requirements and to check for the PD-L1 marker. The study is designed as an open-label trial, which means both the participants and their doctors will know which treatment is being given. This is a platform study using a master protocol, which means it is set up in a way that allows testing of multiple treatment combinations at the same time.

The study aims to find out if giving immune therapy before surgery can help preserve the face and mouth area without affecting how well the cancer is treated. Researchers want to see if this approach can allow some patients to avoid major surgery while still achieving good results in fighting the cancer. The study will compare how well both treatment approaches work and will follow patients for at least two years to check if the cancer comes back and to measure survival rates.

Patients in the study will be randomly assigned to one of two treatment groups. Those receiving immune therapy before surgery will get the medications over a period of several weeks, followed by regular check-ups to see how the cancer responds. Depending on the response, some patients may be able to avoid surgery or have less extensive surgery. The study will also look at quality of life, side effects, treatment costs, and how much treatment each patient needs. Throughout the study, patients will complete questionnaires about their well-being and will have regular medical examinations to monitor their health and any side effects from the treatments.

The purpose of the study is to compare how long patients live when treated with ivonescimab combined with ligufalimab versus pembrolizumab alone, and also to compare ivonescimab alone versus pembrolizumab. The study will only include patients whose tumors test positive for a protein marker called PD-L1, which is measured using a specific scoring system. Patients will be randomly assigned to receive one of the three treatment options, and the study is designed to be open-label, meaning both patients and doctors will know which treatment is being given.

During the study, patients will receive their assigned treatment through an infusion into a vein at regular intervals over a treatment period that can last up to two years. The study doctors will monitor how well the treatment works by checking if tumors shrink or stop growing, and they will also watch for any side effects. Additional assessments will measure how the medications move through the body and whether the immune system develops any reaction to these treatments. Patients participating in this study must not have received previous treatment specifically for their cancer after it has spread or come back, although they may have had earlier treatments when the cancer was first diagnosed.

The purpose of the study is to compare how well the different treatment combinations work against the cancer. Participants will be randomly assigned to receive either the new combination with JNJ-61186372 or the standard treatment. During the study, doctors will monitor how the cancer responds to treatment and track how long participants live. They will also check for any side effects or problems that might occur with the treatments.

Throughout the study, participants will have regular check-ups where doctors will measure the size of the cancer using imaging scans and assess overall health. The study will also look at quality of life and symptoms by asking participants to complete questionnaires about how they are feeling and how the treatment affects their daily activities. Blood samples will be collected to measure medication levels in the body and to check for any immune responses to the treatment. The study will continue for several years to fully understand the long-term effects of these treatment combinations.

The purpose of this research is to test how safe bemarituzumab is and how well it works in treating different types of solid tumors. The study is divided into two parts. In the first part, doctors will closely monitor how patients respond to the medication and any side effects that may occur. In the second part, they will evaluate how effective the medication is at fighting the cancer.

During the study, patients will receive bemarituzumab through regular infusions. The doctors will track the progress of the treatment using different medical tests and imaging scans such as computed tomography (CT) or magnetic resonance imaging (MRI). They will monitor how the tumors respond to the treatment and keep track of any changes in the patient’s health throughout the study period.

The purpose of this research is to determine how well patients respond to treatment when receiving MRG003 alone compared to receiving both MRG003 and pucotenlimab together. After receiving these study medications, all patients will proceed to receive chemoradiotherapy, which combines traditional cancer-fighting drugs with radiation treatment.

During the study, patients will receive the study medications over several weeks. MRG003 is given based on body weight, while pucotenlimab is given at a fixed dose. Doctors will monitor patients’ responses to treatment and check for any side effects throughout the study period. The total treatment period may last up to several months, including the initial medication phase and the following chemoradiotherapy.

Participants in the study will receive an injection of [18F]-olaparib, which is also known by the code name AZD-2281. The study will look at how the substance is absorbed by the body and how it interacts with the cancer cells. This will help researchers determine the best time to perform the imaging scan and how the cancer cells respond to the treatment. The study will also compare the uptake of [18F]-olaparib in the tumor with the levels of a protein called PARP-1 in the cancer cells.

The trial will be conducted in stages, with the first stage focusing on finding the right dosage and timing for the imaging, and the second stage continuing to monitor safety and effectiveness. Participants will be monitored for any side effects for up to 30 days after the injection. The study aims to provide valuable information on how this imaging technique can be used to better understand and treat HNSCC.

The purpose of this research is to evaluate how well the combination of domvanalimab and zimberelimab with chemotherapy works compared to zimberelimab with chemotherapy alone in treating this type of cancer. Both domvanalimab and zimberelimab are types of immunotherapy medications that help the body’s immune system fight cancer cells, while paclitaxel and carboplatin are traditional chemotherapy drugs that directly attack cancer cells.

During the study, participants will receive their assigned treatment combination through regular infusion sessions. The treatments will continue for up to two years, depending on how well they work and how well they are tolerated. Throughout the study, doctors will monitor participants’ health and regularly check how their cancer responds to the treatment using various medical tests and examinations.

The purpose of the study is to evaluate how effective these treatments are when given to patients who have already been treated with a combination of Pembrolizumab and chemotherapy drugs like platinum and 5-FU. Participants will be divided into two groups: one group will receive weekly doses of cetuximab combined with paclitaxel, while the other group will receive cetuximab alone. The study will monitor how well the cancer responds to these treatments.

Throughout the study, participants will receive regular infusions and undergo various assessments to track their health and the cancer’s response to the treatment. The study aims to provide valuable information on the effectiveness of these treatment options for patients with this type of head and neck cancer.

The purpose of the study is to compare the effectiveness of the combination of INBRX-106 and Pembrolizumab against Pembrolizumab alone. Some patients will receive the combination treatment, while others will receive only Pembrolizumab. A third group will receive a placebo, which looks like the treatment but does not contain any active medicine. The study will help determine if adding INBRX-106 to Pembrolizumab provides better outcomes for patients with this type of cancer.

Participants in the study will receive their assigned treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will last for a period of up to 105 weeks, during which time patients will be monitored regularly to assess how well the treatment is working and to check for any side effects. The goal is to find out if the new combination treatment can improve the chances of controlling the cancer and extending the lives of patients with recurrent or metastatic HNSCC.

Participants in the study will receive the treatment through intravenous administration, meaning it will be delivered directly into the bloodstream. The study is divided into two phases. In the first phase, the focus is on determining the safety and the best dose of the MC2 TCR T cells when used with the epigenetic drug. The second phase will assess how well the treatment works in shrinking or controlling the cancer. Throughout the study, doctors will monitor for any side effects and measure how the cancer responds to the treatment.

The trial aims to find out if this new approach can be a viable option for patients with these types of cancer, especially those who have not responded to standard treatments. By using the patient’s own immune cells, which are modified to better fight the cancer, the study hopes to offer a more personalized treatment option. The results will help determine if this therapy can be used more widely in the future for treating advanced melanoma and HNSCC.

The purpose of this research is to determine if patients whose tumors show specific genetic patterns related to oxygen levels can achieve similar treatment outcomes whether they receive nimorazole or not during their radiation therapy. The study uses genetic testing to examine tumor characteristics before treatment begins. Patients will receive radiation therapy, and some will also receive nimorazole tablets and cisplatin infusions as part of their treatment.

During the treatment period, which lasts up to 6 months, patients may receive up to 3,500 mg of nimorazole per day and up to 40 mg/m² of cisplatin. The total amount of nimorazole that may be given throughout the entire treatment period is up to 75,000 mg, while the total amount of cisplatin may reach 70 mg. Doctors will monitor how well the cancer responds to the treatment and track any side effects that may occur.

Participants in the study will receive either Durvalumab alone or a combination of Durvalumab and Tremelimumab. The study will also include a group that receives a placebo. The trial will monitor the biological response of the tumor to these treatments. This means researchers will look at how the cancer cells react to the medications, including any changes in the tumor’s size or behavior. The study will also assess the safety of the treatments and their impact on the participants’ overall health.

The trial will take place over a period of time, during which participants will receive the treatments and undergo various tests and evaluations. These may include imaging tests like PET/MR scans, which help visualize the inside of the body, and assessments of the participants’ health and well-being. The study aims to gather information that could lead to better treatment options for people with this type of cancer in the future.

Participants in the study will receive the treatment as a solution for infusion, which means it will be given through a vein. The study will observe how the treatment affects the cancer and monitor any side effects. The trial will include regular check-ups and assessments to track the progress of the treatment. The study aims to understand how well the treatment works in shrinking the tumors and how safe it is for the patients.

The study will continue for several years, with the goal of gathering enough information to determine the treatment’s effectiveness and safety. This research is important for developing new ways to treat these challenging cancers and could potentially lead to new treatment options for patients in the future.

The purpose of this study is to find the best dose of Fianlimab and the best time to perform a special type of imaging called PET scan to see how the treatment is working. A PET scan is a test that helps doctors see how organs and tissues inside the body are functioning. The study will also look at how safe Fianlimab is for patients. Participants will receive the treatment and undergo PET scans before and during their treatment with Cemiplimab, with or without chemotherapy. The study will help researchers understand how the treatment affects the body and how well it works against the cancer.

Throughout the study, patients will be monitored closely to ensure their safety and to observe any changes in their condition. The study aims to provide valuable information that could lead to better treatment options for people with advanced solid cancers. By understanding how these medications work together, researchers hope to improve outcomes for patients facing these challenging diseases.

Participants in the study will receive the treatment over a period of time, with regular check-ups to monitor their health and the cancer’s response to the treatment. The study will look at how well the treatment controls the cancer in the neck and whether it causes any side effects. The study will also assess the overall health and survival of the participants, as well as their quality of life during and after the treatment.

This trial is important for understanding the effectiveness and safety of combining durvalumab with radiotherapy for treating squamous cell carcinoma of the head and neck. The results could help improve treatment options for patients with this type of cancer in the future.

Participants in the study will receive treatment through an infusion, which means the medication is given directly into the bloodstream through a vein. The study will compare the effects of the combination of nivolumab and cisplatin with radiotherapy to the effects of cisplatin and radiotherapy alone. Some participants will receive a placebo instead of nivolumab to help researchers understand the true effects of the medication. The study will last for several months, and participants will have regular check-ups and imaging tests to monitor their health and the progress of the cancer.

The main goal is to determine if the combination treatment can help patients live longer without the cancer coming back. Researchers will also look at overall survival rates and any side effects that may occur. This study is important because it could lead to better treatment options for people with high-risk squamous cell carcinoma of the head and neck who have already had surgery to remove the cancer.

The purpose of the study is to evaluate how effective these treatments are in patients whose cancer has returned or spread and is positive for a protein called PD-L1. Participants will receive the treatments through an intravenous (IV) infusion, which means the medication is given directly into a vein. The study will last for up to 24 months, during which time the response to the treatment will be monitored. This includes checking how well the cancer responds to the treatment and how long the response lasts.

Throughout the study, researchers will also look at other important factors, such as how long patients live without the cancer getting worse, overall survival rates, and any side effects experienced. The study aims to provide valuable information on the potential benefits of combining atezolizumab with tiragolumab for treating this type of cancer.

The purpose of the study is to evaluate how effective and safe it is to use fewer chemotherapy cycles along with Pembrolizumab for treating this type of cancer. Participants in the study will receive these treatments and will be monitored to see how their cancer responds and to check for any side effects. The study will help determine if a shorter course of chemotherapy can still be effective when combined with Pembrolizumab.

Throughout the study, participants will receive regular check-ups and assessments to track their progress. The study aims to provide valuable information on whether reducing chemotherapy cycles can maintain treatment effectiveness while potentially reducing side effects. This research could lead to improved treatment options for patients with PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma.

The purpose of this research is to determine if petosemtamab is more effective than currently available treatments in helping patients with head and neck cancer live longer and to see how well tumors respond to the treatment. The study is designed for patients whose cancer has continued to grow despite previous treatment with platinum-containing therapy and immune therapy.

During the study, participants will be randomly assigned to receive either petosemtamab or one of the standard treatments. All medications will be given through an intravenous infusion. The treatment period will last up to 6 months, depending on how well the treatment works and how well it is tolerated. Throughout the study, patients will have regular check-ups to monitor their health and assess how their cancer responds to treatment.

Both medications are given through an intravenous infusion (directly into a vein). Petosemtamab can be given at doses up to 1500 milligrams per day, while pembrolizumab can be given at doses up to 400 milligrams per day. The purpose of this study is to determine if combining these two medications works better than using pembrolizumab by itself for patients who have not received previous treatment for their advanced cancer.

The treatment period may last up to 24 months. During the study, patients will have regular check-ups to monitor their health and how well the treatment is working. The study will look at how long patients live and whether their tumors shrink in response to the treatment.

The purpose of the study is to understand how effective these treatments are when used together. Participants will be divided into two groups. One group will receive both Niraparib and Dostarlimab along with radiotherapy and a chemotherapy drug called cisplatin. The other group will receive Niraparib and Dostarlimab with radiotherapy, but without cisplatin, as some patients may not be suitable for cisplatin treatment. The study will monitor the participants over time to see how well the cancer responds to the treatment and to check for any side effects.

The study will last several years, with regular check-ups and assessments to track the progress of the disease and the participants’ health. The main goal is to see if the combination of these treatments can help prevent the cancer from returning within a year. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

The purpose of the study is to compare the effectiveness of these two treatment methods in preventing the progression of the disease. Participants will be randomly assigned to one of the two treatment groups. Throughout the study, participants will receive regular assessments to monitor their health and the progression of their condition. The study aims to determine which treatment approach offers better outcomes in terms of progression-free survival, which refers to the length of time during and after treatment that a patient lives with the disease without it getting worse.

In addition to progression-free survival, the study will also look at other important factors such as overall survival, quality of life, and the time it takes for the disease to progress locally or spread to other parts of the body. The study will also monitor any side effects that participants may experience, particularly those that are severe. The trial is expected to continue until 2030, with recruitment starting in 2024.

The purpose of the study is to determine if the new combination of avelumab and cetuximab with radiotherapy is better than the standard treatments in preventing the cancer from getting worse. Participants in the study will be randomly assigned to receive either the new combination treatment or one of the standard treatments. The study will monitor the participants over time to see how well the treatments work and to check for any side effects. The trial will also look at how the treatments affect the participants’ quality of life, including their ability to swallow and speak.

This study is important because it aims to find more effective treatments for people with locally advanced squamous cell carcinoma of the head and neck. By comparing the new combination treatment to the standard treatments, researchers hope to improve outcomes for patients with this type of cancer. The study will continue until the end of 2027, and the results will help guide future treatment options for this disease.

The purpose of the study is to see how these treatments affect the body’s immune system, specifically looking at a type of immune cell called a T-cell. The study will last for about three weeks, during which participants will receive one of the treatments before starting their standard cancer treatment. The study will monitor the safety and effects of these treatments on the cancer and the immune system.

Participants will be closely observed to see how their bodies respond to the treatment, including any changes in their cancer and any side effects they might experience. The study aims to gather information on how well these treatments work on their own before the usual cancer treatments begin. This research could help improve future treatment options for people with head and neck cancer.

The purpose of the study is to see how well this combination of treatments works in patients who have not responded to their first treatment. Participants in the study will receive the combination of Carboplatin, Paclitaxel, and Cetuximab over a period of time. The study will monitor how the cancer responds to these treatments and will also keep track of any side effects that may occur. The study aims to understand the effectiveness of this treatment combination in managing the cancer and improving patient outcomes.

Throughout the study, researchers will collect information on how the cancer progresses and how patients are doing overall. This includes looking at whether the cancer shrinks or grows, and how long patients live after starting the treatment. The study will also gather information on any side effects experienced by the patients. This information will help doctors understand if this treatment combination is a good option for patients with head and neck squamous cell carcinoma who have not had success with their initial treatment.

Participants in the study will receive the medications through an infusion, which means the drugs are given directly into the bloodstream. The study will observe how the tumors respond to the treatment over a period of time. The trial is designed to see if the combination of Tiragolumab and Tecentriq can help shrink the tumors or stop them from growing. The study will also monitor the safety of the medications and any side effects that may occur.

The trial is open-label, meaning both the researchers and participants know which treatment is being administered. The study will include different groups of patients, each with specific types of cancer, to determine the effectiveness of the treatment across various conditions. The trial aims to provide valuable information on whether these medications can be beneficial for patients with these types of cancer.

The purpose of the study is to see if giving a low dose of cisplatin every week helps patients stick to their treatment plan better than the high dose given every three weeks. The study will involve patients receiving either the weekly low dose or the three-weekly high dose of cisplatin, along with their regular cancer treatment. The researchers will monitor how well patients can follow their treatment schedule and any side effects they experience. The study will also look at other factors like the total amount of cisplatin received, the time it takes for the cancer to come back, and the overall survival of the patients over two years.

Throughout the study, the medical team will keep track of any side effects or toxicities that patients might experience, especially those that are severe. They will also consider the quality of life of the patients and their preferences regarding the treatment. The study aims to provide valuable information on the best way to use cisplatin in treating head and neck cancer in patients with low muscle mass, potentially improving treatment outcomes and patient well-being.

The treatment plan consists of two phases. In the first phase, patients will receive TPEx therapy which includes docetaxel, cisplatin or carboplatin, and cetuximab. After this initial treatment, patients will continue with maintenance therapy using a combination of avelumab and cetuximab. Both medications are given through an infusion into a vein.

The main purpose of this study is to determine how well this combination treatment works in terms of helping patients live longer. The study will also track how the disease responds to treatment and monitor any side effects that patients may experience, particularly during the maintenance phase of treatment with avelumab and cetuximab.